Company Encyclopedia
View More
name
Cyclo Therapeutics
CYTH.US
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc.
1.897 T
CYTH.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking0/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE341.45%A
    • Profit Margin-2848.16%E
    • Gross Margin91.32%A
  • Growth ScoreD
    • Revenue YoY-8.52%D
    • Net Profit YoY-27.86%D
    • Total Assets YoY-6.13%D
    • Net Assets YoY-1179.92%E
  • Cash ScoreD
    • Cash Flow Margin-3.51%D
    • OCF YoY-8.52%D
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreE
    • Gearing Ratio356.44%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee ( DMC ) following their review of prespecified safety and ...

    GlobeNewswire·
    US
    CYTH
    0.00%
    GlobeNewswire·
    US
    CYTH
    0.00%

    Cyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025

    Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, will present research on Niemann-Pick Disease at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The presentations will include an oral discussion on the efficacy and safety of Hydroxypropyl-beta-cyclodextrin and a poster on open-label treatment in young patients.

    Reuters·
    US
    CYTH
    0.00%
    Reuters·
    US
    CYTH
    0.00%

    Cyclo Therapeutics' Phase 3 NPC1 Study Advances with Positive Interim Data Review

    Cyclo Therapeutics, a subsidiary of Rafael Holdings, is progressing with its Phase 3 TransportNPC study for the treatment of Niemann-Pick Disease Type C1 (NPC1) using Trappsol® Cyclo™. The study continues after a positive interim review by an independent Data Monitoring Committee, confirming safety and efficacy at the 48-week mark. The FDA has approved the statistical analysis plan, and the investigational candidate shows a safety profile consistent with earlier studies. This study is noted for its comprehensive scale and clinical outcomes assessment.

    Reuters·
    US
    CYTH
    0.00%
    Reuters·
    US
    CYTH
    0.00%

    Rafael Holdings reports Q3 financials; Cyclo Therapeutics' Phase 3 trial for Niemann-Pick Disease fully enrolled, results due this month.

    Cyclo Therapeutics has successfully enrolled all participants in the Phase 3 clinical trial of TransportNPC™ for the treatment of Niemann-Pick Disease Type C1. This rare genetic disease is known to be fatal. The trial involves the use of Trappsol® Cyclo™ and results from the 48-week interim analysis are anticipated to be released within the current month. This development marks a significant advancement in the efforts to combat this severe condition.

    Unusual Whales·
    US
    CYTH
    0.00%
    Unusual Whales·
    US
    CYTH
    0.00%

    Rafael Holdings prioritizes Trappsol Cyclo development, CEO stepping down. TransportNPC Phase 3 trial fully enrolled, results in mid-2025.

    The Phase 3 clinical trial of TransportNPC™ by Cyclo Therapeutics for treating Niemann-Pick Disease Type C1, a rare genetic condition, has completed enrollment. The trial is evaluating Trappsol® Cyclo™ and interim analysis results are anticipated in mid-2025 after 48 weeks of study. This marks a significant advancement in the research for this fatal disease.

    Unusual Whales·
    US
    CYTH
    0.00%
    Unusual Whales·
    US
    CYTH
    0.00%